NasdaqCM:CDTXBiotechs
How Investors Are Reacting To Cidara Therapeutics (CDTX) Securing Major Funding and FDA Breakthrough for CD388
Cidara Therapeutics recently announced progress in its Phase 3 ANCHOR study for CD388, securing a US$45 million milestone payment from Janssen, a BARDA award valued up to US$339.2 million to support manufacturing, and receiving FDA Breakthrough Therapy designation.
These updates highlight the growing validation and financial support behind CD388, a promising immunotherapeutic candidate for influenza prevention and serious diseases.
We'll explore how the combination of clinical and funding...